Developer docs
API playgroundTry for free, no card

Search company profiles

Kiniksa Pharmaceuticals

Full company profile

uuid0003wu9

Namestring
Kiniksa Pharmaceuticals
Legal namestring
Kiniksa Pharmaceuticals International, plc
Websiteurl
kiniksa.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Bermuda (incorporated in the UK), listed on NASDAQ under ticker KNSA. The company develops and commercializes immune-modulating therapies targeting inflammatory and autoimmune diseases with high unmet need, with a strategic focus on cardiovascular indications. Its core product is ARCALYST (rilonacept), an IL-1α and IL-1β inhibitor that became the first and only FDA-approved therapy for recurrent pericarditis in March 2021, also approved for CAPS and DIRA. The clinical pipeline includes KPL-387 (Phase 2/3 IL-1 receptor antagonist mAb for recurrent pericarditis), Mavrilimumab (Phase 1 GM-CSFRα mAb for rare cardiovascular diseases), and KPL-404 (Phase 2 anti-CD40 mAb for rheumatoid arthritis), while vixarelimab is licensed globally to Roche and Genentech.

Kiniksa operates a specialty pharmaceutical commercial model, generating 100% of revenue from ARCALYST product sales through specialty pharmacy distribution channels and a field sales organization targeting specialist physicians including cardiologists and rheumatologists. The company had 4,550+ prescribing physicians and an estimated ~18% penetration of the addressable recurrent pericarditis patient population as of year-end 2025. ARCALYST delivered $677.6M in FY2025 revenue (62% YoY growth) and $214.3M in Q1 2026 (56% YoY growth), with 2026 guidance raised to $930-$945M. The company turned profitable in 2025 ($59M net income vs. $43.2M net loss in 2024), holds $468.1M in cash with no debt, and supports its franchise through the Kiniksa OneConnect patient services program, the RESONANCE Patient Registry, and disease-awareness initiatives including a DTC television campaign launched in April 2026.

The business is supported by a senior leadership team with deep rare-disease commercialization experience — most notably CEO Sanj K. Patel, who previously built and sold Synageva to Alexion for $9.7B in 2015. Geographic reach includes the US, UK, Switzerland, and Asia Pacific (via a Huadong Medicine partnership for ARCALYST and mavrilimumab, excluding Japan). The company is rated No. 1 in its industry group on the IBD Relative Strength Rating (93) as of 2026, with a market capitalization of approximately $3.59B.

Short descriptiontext

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes immune-modulating therapies, anchored by ARCALYST — the first and only FDA-approved treatment for recurrent pericarditis — serving patients with inflammatory and autoimmune diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical therapies, IL-1 pathway inhibition, recurrent pericarditis treatment, orphan drug development, autoimmune disease therapies
Industry2 codes
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1ARCALYST Product Sales
TypeOne Time License
Description

Commercial drug sales from ARCALYST (rilonacept), FDA-approved therapy for recurrent pericarditis, CAPS, and DIRA. Company generates 100% of revenue from this single drug.

globenewswire.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1ARCALYST prescription drug pricing
ModelOtherBilling cadenceOther
Notes

Quote-based / Not publicly disclosed

globenewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ARCALYST
Description

FDA-approved therapy for recurrent pericarditis, CAPS, and DIRA. IL-1α and IL-1β inhibitor.

clinicaltrials.kiniksa.com
+1 more record
Core offering1 text field

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes immune-modulating therapies for inflammatory and autoimmune diseases. Its commercial product, ARCALYST (rilonacept), is an IL-1α and IL-1β inhibitor and the first and only FDA-approved therapy for recurrent pericarditis, also approved for CAPS and DIRA. The company also maintains a clinical-stage pipeline including KPL-387, mavrilimumab, KPL-404, and vixarelimab targeting serious diseases with unmet medical needs with a focus on cardiovascular indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 56% year-over-year revenue growth in Q1 2026
+3 more records
Product overview1 text field

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with an FDA-approved therapy and clinical-stage pipeline targeting serious diseases with unmet medical needs, focused on cardiovascular indications. The core product is ARCALYST (rilonacept), an IL-1α and IL-1β inhibitor approved for recurrent pericarditis, CAPS, and DIRA. The pipeline includes KPL-387 (Phase 2/3 for recurrent pericarditis), Mavrilimumab (Phase 1 for rare cardiovascular diseases), KPL-404 (Phase 2 for rheumatoid arthritis), and Vixarelimab (Roche/Genentech global rights). Patient support is provided through Kiniksa OneConnect program, and research efforts are supported by the RESONANCE patient registry.

Product and service7 records
1ARCALYST (rilonacept)
CategoryCore commercial pharmaceutical product
Description

FDA-approved IL-1α and IL-1β inhibitor for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), and deficiency of interleukin-1 receptor antagonist (DIRA). The therapy addresses inflammatory conditions through IL-1 pathway inhibition, representing the first and only FDA-approved therapy for recurrent pericarditis in adults and pediatric patients 12 years and older.

2KPL-387
CategoryPipeline pharmaceutical product (clinical-stage)
Description

Investigational monoclonal antibody IL-1 receptor antagonist in liquid formulation with once-monthly subcutaneous dosing target profile for recurrent pericarditis treatment. Currently in Phase 2/3 clinical development (KPL-387-C211 trial). Efficacy and safety have not been evaluated by any regulatory authority.

3Mavrilimumab
CategoryPipeline pharmaceutical product (clinical-stage)
Description

GM-CSFRα targeting agent in Phase 1 development evaluating rare cardiovascular diseases. Kiniksa holds worldwide rights excluding Middle East and North Africa.

4KPL-404 (Abiprubart)
CategoryPipeline pharmaceutical product (clinical-stage)
Description

Anti-CD40 monoclonal antibody in Phase 2 development for rheumatoid arthritis. Worldwide rights held by Kiniksa.

5Vixarelimab
CategoryOut-licensed pharmaceutical asset
Description

OSMRβ targeting antibody previously licensed through global license agreement. Global rights held by Roche and Genentech for all indications; Kiniksa no longer commercializes this asset.

6Kiniksa OneConnect
CategoryPatient support service
Description

Patient support program providing personalized one-on-one support throughout the treatment journey, including financial assistance options for patients with recurrent pericarditis, CAPS, and DIRA.

7RESONANCE Patient Registry
CategoryResearch registry
Description

Voluntary patient-powered registry and network of physicians and researchers dedicated to advancing research efforts in recurrent pericarditis.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierGlobalTypeStrategic or Co-development PartnerAnnounced on2022-07-01
Description

Global license agreement with Roche and Genentech for rights to develop and commercialize vixarelinmab. Roche and Genentech hold global rights for all indications.

2Huadong Medicine
Strategic tierRegionalTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Strategic collaboration to develop and commercialize ARCALYST (rilonacept) and mavrilimumab in the Asia Pacific Region, excluding Japan. Huadong Medicine holds exclusive rights in this territory.

kiniksa.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

BioMarin is a larger rare-disease specialty biopharma with multiple Orphan Drug therapies. While broader than Kiniksa, BioMarin represents a relevant comparable for specialty pharma commercial scaling and pipeline diversification.

TypeEmerging player
Description

Apellis commercializes rare autoimmune ophthalmology therapies (Empaveli, Syfovre) using specialty pharmacy channels and rare-disease commercial infrastructure, with a similar growth profile and prescriber specialization.

TypeBroad incumbent
Description

Regeneron is the original developer of rilonacept (ARCALYST) and licenses the trademark to Kiniksa. It is a broad incumbent in IL-1/inflammation biologics with Dupixent and other franchises, providing both competitive overlap and a strategic relationship with Kiniksa.

TypeDirect peer
Description

Corcept is a specialty biopharma built around a single commercialized therapy (Korlym) with a focused sales force targeting specialist physicians, mirroring Kiniksa's orphan/specialty model and revenue trajectory.

TypeDirect peer
Description

Madrigal is a commercial-stage specialty biopharma that recently launched Rezdiffra, with comparable growth acceleration and specialty physician targeting. Both companies share a similar inflection from clinical-stage to commercial specialty pharma.

TypeDirect peer
Description

Sobi markets Kineret (anakinra), an IL-1 receptor antagonist, and is a major rare-disease specialty biopharma. Sobi competes directly in IL-1 biology for inflammatory conditions and shares Kiniksa's orphan/specialty commercial model.

TypeDirect peer
Description

Ultragenyx is a rare-disease commercial biopharma with multiple Orphan Drug-designated therapies and a focus on genetically defined conditions, comparable to Kiniksa's orphan/specialty strategy and pipeline depth.

8ChemoCentryx
TypeEmerging player
Description

ChemoCentryx (acquired by Amgen in 2022) was a rare autoimmune biopharma with Taveglin for ANCA-associated vasculitis, sharing Kiniksa's IL-pathway inflammation focus and orphan/specialty commercial approach.

TypeDirect peer
Description

Travere is a rare-disease specialty biopharma with commercial products and pipeline assets in nephrology and rare metabolic conditions, comparable in patient population targeting, regulatory strategy (Orphan Drug), and commercial-stage evolution.

TypeBroad incumbent
Description

Vertex is a broad specialty biopharma with rare disease franchises (CF, sickle cell) and a track record of converting rare disease leadership into a multi-billion-dollar franchise, providing a relevant comparable for Kiniksa's longer-term scaling potential.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kiniksa Pharmaceuticals

Specialty Biopharmaceuticalskiniksa.com

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes immune-modulating therapies, anchored by ARCALYST — the first and only FDA-approved treatment for recurrent pericarditis — serving patients with inflammatory and autoimmune diseases.

What Kiniksa Pharmaceuticals does

Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Bermuda (incorporated in the UK), listed on NASDAQ under ticker KNSA. The company develops and commercializes immune-modulating therapies targeting inflammatory and autoimmune diseases with high unmet need, with a strategic focus on cardiovascular indications. Its core product is ARCALYST (rilonacept), an IL-1α and IL-1β inhibitor that became the first and only FDA-approved therapy for recurrent pericarditis in March 2021, also approved for CAPS and DIRA. The clinical pipeline includes KPL-387 (Phase 2/3 IL-1 receptor antagonist mAb for recurrent pericarditis), Mavrilimumab (Phase 1 GM-CSFRα mAb for rare cardiovascular diseases), and KPL-404 (Phase 2 anti-CD40 mAb for rheumatoid arthritis), while vixarelimab is licensed globally to Roche and Genentech.

Kiniksa operates a specialty pharmaceutical commercial model, generating 100% of revenue from ARCALYST product sales through specialty pharmacy distribution channels and a field sales organization targeting specialist physicians including cardiologists and rheumatologists. The company had 4,550+ prescribing physicians and an estimated ~18% penetration of the addressable recurrent pericarditis patient population as of year-end 2025. ARCALYST delivered $677.6M in FY2025 revenue (62% YoY growth) and $214.3M in Q1 2026 (56% YoY growth), with 2026 guidance raised to $930-$945M. The company turned profitable in 2025 ($59M net income vs. $43.2M net loss in 2024), holds $468.1M in cash with no debt, and supports its franchise through the Kiniksa OneConnect patient services program, the RESONANCE Patient Registry, and disease-awareness initiatives including a DTC television campaign launched in April 2026.

The business is supported by a senior leadership team with deep rare-disease commercialization experience — most notably CEO Sanj K. Patel, who previously built and sold Synageva to Alexion for $9.7B in 2015. Geographic reach includes the US, UK, Switzerland, and Asia Pacific (via a Huadong Medicine partnership for ARCALYST and mavrilimumab, excluding Japan). The company is rated No. 1 in its industry group on the IBD Relative Strength Rating (93) as of 2026, with a market capitalization of approximately $3.59B.

Kiniksa Pharmaceuticals firmographics

Firmographics
Name
Kiniksa Pharmaceuticals
Legal name
Kiniksa Pharmaceuticals International, plc
Website
https://kiniksa.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes immune-modulating therapies, anchored by ARCALYST — the first and only FDA-approved treatment for recurrent pericarditis — serving patients with inflammatory and autoimmune diseases.
Ownership category
akta.pro rank

Kiniksa Pharmaceuticals industry classification

Industry
Product category
Specialty Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Biopharmaceutical therapies
  • IL-1 pathway inhibition
  • Recurrent pericarditis treatment
  • Orphan drug development
  • Autoimmune disease therapies

Where Kiniksa Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Kiniksa Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. ARCALYST Product Sales: Commercial drug sales from ARCALYST (rilonacept), FDA-approved therapy for recurrent pericarditis, CAPS, and DIRA. Company generates 100% of revenue from this single drug.

Pricing tiers

ModelBillingPrice
OtherOtherARCALYST prescription drug pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Kiniksa Pharmaceuticals product offering

Product offering

Core offering

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes immune-modulating therapies for inflammatory and autoimmune diseases. Its commercial product, ARCALYST (rilonacept), is an IL-1α and IL-1β inhibitor and the first and only FDA-approved therapy for recurrent pericarditis, also approved for CAPS and DIRA. The company also maintains a clinical-stage pipeline including KPL-387, mavrilimumab, KPL-404, and vixarelimab targeting serious diseases with unmet medical needs with a focus on cardiovascular indications.

Product overview

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with an FDA-approved therapy and clinical-stage pipeline targeting serious diseases with unmet medical needs, focused on cardiovascular indications. The core product is ARCALYST (rilonacept), an IL-1α and IL-1β inhibitor approved for recurrent pericarditis, CAPS, and DIRA. The pipeline includes KPL-387 (Phase 2/3 for recurrent pericarditis), Mavrilimumab (Phase 1 for rare cardiovascular diseases), KPL-404 (Phase 2 for rheumatoid arthritis), and Vixarelimab (Roche/Genentech global rights). Patient support is provided through Kiniksa OneConnect program, and research efforts are supported by the RESONANCE patient registry.

Differentiator

Problem solved

Functional benefit

Brands

  • ARCALYST: FDA-approved therapy for recurrent pericarditis, CAPS, and DIRA. IL-1α and IL-1β inhibitor.
  • Kiniksa OneConnect

Products and services

  • ARCALYST (rilonacept) FDA-approved IL-1α and IL-1β inhibitor for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), and deficiency of interleukin-1 receptor antagonist (DIRA). The therapy addresses inflammatory conditions through IL-1 pathway inhibition, representing the first and only FDA-approved therapy for recurrent pericarditis in adults and pediatric patients 12 years and older.
  • KPL-387 Investigational monoclonal antibody IL-1 receptor antagonist in liquid formulation with once-monthly subcutaneous dosing target profile for recurrent pericarditis treatment. Currently in Phase 2/3 clinical development (KPL-387-C211 trial). Efficacy and safety have not been evaluated by any regulatory authority.
  • Mavrilimumab GM-CSFRα targeting agent in Phase 1 development evaluating rare cardiovascular diseases. Kiniksa holds worldwide rights excluding Middle East and North Africa.
  • KPL-404 (Abiprubart) Anti-CD40 monoclonal antibody in Phase 2 development for rheumatoid arthritis. Worldwide rights held by Kiniksa.
  • Vixarelimab OSMRβ targeting antibody previously licensed through global license agreement. Global rights held by Roche and Genentech for all indications; Kiniksa no longer commercializes this asset.
  • Kiniksa OneConnect Patient support program providing personalized one-on-one support throughout the treatment journey, including financial assistance options for patients with recurrent pericarditis, CAPS, and DIRA.
  • RESONANCE Patient Registry Voluntary patient-powered registry and network of physicians and researchers dedicated to advancing research efforts in recurrent pericarditis.

Quantifiable outcome

  • 56% year-over-year revenue growth in Q1 2026
  • +3 more outcomes

Companies that use Kiniksa Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Kiniksa Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Kiniksa Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered global and regional.

  • Roche and GenentechglobalStrategic or Co-development Partner · 1 July 2022Global license agreement with Roche and Genentech for rights to develop and commercialize vixarelinmab. Roche and Genentech hold global rights for all indications.
  • Huadong MedicineregionalStrategic or Co-development Partner · 1 January 2022Strategic collaboration to develop and commercialize ARCALYST (rilonacept) and mavrilimumab in the Asia Pacific Region, excluding Japan. Huadong Medicine holds exclusive rights in this territory.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Kiniksa Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is a larger rare-disease specialty biopharma with multiple Orphan Drug therapies. While broader than Kiniksa, BioMarin represents a relevant comparable for specialty pharma commercial scaling and pipeline diversification.
  • Regeneron Pharmaceuticals: Regeneron is the original developer of rilonacept (ARCALYST) and licenses the trademark to Kiniksa. It is a broad incumbent in IL-1/inflammation biologics with Dupixent and other franchises, providing both competitive overlap and a strategic relationship with Kiniksa.
  • Vertex Pharmaceuticals: Vertex is a broad specialty biopharma with rare disease franchises (CF, sickle cell) and a track record of converting rare disease leadership into a multi-billion-dollar franchise, providing a relevant comparable for Kiniksa's longer-term scaling potential.

Emerging players

  • Apellis Pharmaceuticals: Apellis commercializes rare autoimmune ophthalmology therapies (Empaveli, Syfovre) using specialty pharmacy channels and rare-disease commercial infrastructure, with a similar growth profile and prescriber specialization.
  • ChemoCentryx: ChemoCentryx (acquired by Amgen in 2022) was a rare autoimmune biopharma with Taveglin for ANCA-associated vasculitis, sharing Kiniksa's IL-pathway inflammation focus and orphan/specialty commercial approach.

Direct peers

  • Corcept Therapeutics: Corcept is a specialty biopharma built around a single commercialized therapy (Korlym) with a focused sales force targeting specialist physicians, mirroring Kiniksa's orphan/specialty model and revenue trajectory.
  • Madrigal Pharmaceuticals: Madrigal is a commercial-stage specialty biopharma that recently launched Rezdiffra, with comparable growth acceleration and specialty physician targeting. Both companies share a similar inflection from clinical-stage to commercial specialty pharma.
  • Swedish Orphan Biovitrum (Sobi): Sobi markets Kineret (anakinra), an IL-1 receptor antagonist, and is a major rare-disease specialty biopharma. Sobi competes directly in IL-1 biology for inflammatory conditions and shares Kiniksa's orphan/specialty commercial model.
  • Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease commercial biopharma with multiple Orphan Drug-designated therapies and a focus on genetically defined conditions, comparable to Kiniksa's orphan/specialty strategy and pipeline depth.
  • Travere Therapeutics: Travere is a rare-disease specialty biopharma with commercial products and pipeline assets in nephrology and rare metabolic conditions, comparable in patient population targeting, regulatory strategy (Orphan Drug), and commercial-stage evolution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kiniksa Pharmaceuticals social profiles

Digital presence

Kiniksa Pharmaceuticals compliance and trust

Trust signal

Compliance5 records

Kiniksa Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kiniksa Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

Kiniksa Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kiniksa Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kiniksa Pharmaceuticals

What does Kiniksa Pharmaceuticals do?

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes immune-modulating therapies for inflammatory and autoimmune diseases. Its commercial product, ARCALYST (rilonacept), is an IL-1α and IL-1β inhibitor and the first and only FDA-approved therapy for recurrent pericarditis, also approved for CAPS and DIRA. The company also maintains a clinical-stage pipeline including KPL-387, mavrilimumab, KPL-404, and vixarelimab targeting serious diseases with unmet medical needs with a focus on cardiovascular indications.

Is Kiniksa Pharmaceuticals a public or private company?

Kiniksa Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Kiniksa Pharmaceuticals founded?

Kiniksa Pharmaceuticals was founded in 2015. It employs 251 to 500 people.

Where is Kiniksa Pharmaceuticals based?

Kiniksa Pharmaceuticals is headquartered in Lexington, United States, in the North America region.

How does Kiniksa Pharmaceuticals make money?

One revenue line is on record: ARCALYST Product Sales.

Who are Kiniksa Pharmaceuticals's main competitors?

Broad incumbents on record are BioMarin Pharmaceutical, Regeneron Pharmaceuticals and Vertex Pharmaceuticals. Emerging players are Apellis Pharmaceuticals and ChemoCentryx. Direct peers are Corcept Therapeutics, Madrigal Pharmaceuticals, Swedish Orphan Biovitrum (Sobi), Ultragenyx Pharmaceutical and Travere Therapeutics.

Does Kiniksa Pharmaceuticals have an API?

No public API is recorded for Kiniksa Pharmaceuticals.

What industry is Kiniksa Pharmaceuticals in?

Kiniksa Pharmaceuticals's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies, with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewTD Cowen maintains Kiniksa Pharmaceuticals at Buy, raises price target to $115 from $100TD Cowen maintained Kiniksa Pharmaceuticals at Buy and raised its price target to $115 from $100, a 15% increase. The target implies a 22% upside from the Nov 16 close of $94.23. Recent analyst price targets range from $101 to $122.Defense WorldKiniksa Pharmaceuticals International, plc $KNSA Stock: Aberdeen Group plc Reduces StakeAberdeen Group reduced its stake in Kiniksa Pharmaceuticals by 13.9% in Q3, selling 56,191 shares. The company reported Q3 EPS of $0.56, beating estimates, with revenue of $285.97 million. Analysts have a consensus price target of $100.57.Investing.comKiniksa at Jefferies Global Healthcare Conference: arcalyst growth rolls onKiniksa Pharmaceuticals presented at Jefferies' conference, raising its full-year 2026 revenue guidance to $1.045–1.050 billion, driven by new patient starts on ARCALYST. The drug has reached 23% penetration in the two-plus recurrence market, with KPL-387 in Phase III and KPL-1161 expected in clinical development later in 2026.Defense World74,458 Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Fisher Asset Management LLCFisher Asset Management LLC trimmed its Kiniksa Pharmaceuticals position by 18.7% in Q3, selling 74,458 shares. Analysts have a consensus "Moderate Buy" rating with a price target of $100.57, and the stock closed at $96.33.Simply Wall StWhat Kiniksa Buyers Were Betting On Before A 139% RallyKiniksa Pharmaceuticals International shares rose 138.9% over the past year, with Q3 2026 revenue of $285.97 million and net income of $47.35 million. The company's ARCALYST guidance of $980–995 million net revenue for 2026 and pipeline progress support the bullish case. The current price of $96.33 assumes higher earnings power than prior views.Business & FinancialKiniksa Pharmaceuticals To Present At Jefferies Global Healthcare Conference In LondonKiniksa Pharmaceuticals will present at the Jefferies Global Healthcare Conference in London, with a live webcast available on the company's website. A replay will be posted within approximately 48 hours after the event.FinanzNachrichten.deMilliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo NordiskCardiol Therapeutics is developing oral therapies for inflammatory heart diseases, with Kiniksa and Novo Nordisk also in the pipeline. The only approved drug for recurrent pericarditis is expected to break the $1 billion revenue mark this year. Oral treatments aim to expand access for a broader patient population.Simply Wall StIs Kiniksa Pharmaceuticals International (KNSA) Undervalued As Earnings Per Share Keeps Improving?Kiniksa Pharmaceuticals International reported higher basic and diluted EPS in Q3, with shares rising 6.25% in one day and 17.65% over 30 days. Analysts value the stock at $103.63, a 9% discount, but its P/E of 67.3x far exceeds sector and peer averages.Simply Wall StThe Bet Behind Kiniksa’s 123% RunKiniksa Pharmaceuticals International shares rose 123.4% from the start of the year, driven by revenue growth from $180.86m to $285.97m and net income from $18.44m to $47.35m. Net margin improved from 10.2% to 16.6%, supporting the optimistic valuation thesis. The stock now trades at $93.86, with fair value above that level.American Banking and Market NewsKiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Sanj Patel Sells 151,300 SharesCEO Sanj Patel sold 151,300 Kiniksa Pharmaceuticals shares on November 4th at $94.71, totaling $14.33 million. The sale reduced his ownership by 16.34% to 774,500 shares. The stock opened at $93.86, and analysts rate it a Moderate Buy with a $100.57 price target.